2 years ago
MNMD
AnalystsFrancois BriseboisFrancois Brisebois's Stock Forecasts
AnalystsFrancois Brisebois
Analyst Ranking
Bottom 6%
#4319 out of 4571 analysts
Average Return
-7.67%
Win Rate
38%24 out of 63
Risk vs Reward
Poor
Good
Francois Brisebois's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Mind Medicine IncMNMD | +206.01% | $3.16 | $9.67 | 2023-04-13 - 2024-04-12 | Buy |
Mediwound LtdMDWD | +112.66% | $8.75 | $18.61 | 2023-08-16 - 2024-04-30 | Buy |
Mediwound LtdMDWD | +103.83% | $9.13 | $18.61 | 2023-05-30 - 2024-04-30 | Buy |
Tarsus Pharmaceuticals IncTARS | +101.60% | $15.59 | $31.43 | 2023-05-07 - 2024-04-30 | Buy |
Dyne Therapeutics IncDYN | +76.83% | $13.68 | $24.19 | 2023-02-14 - 2024-02-14 | Buy |
Francois Brisebois Analyst Color
Get additional color on Francois Brisebois's coverage of popular stocks
Francois Brisebois's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Aldeyra Therapeutics IncALDX | 1 | Buy | $10.00 | +153.81% | Upgrades | a month ago |
Kala Bio IncKALA | 1 | Buy | $15.00 | +119.94% | Reiterates | a month ago |
Durect CorpDRRX | 2 | Buy | $5.00 | +420.83% | Reiterates | a month ago |
Achieve Life Sciences IncACHV | 4 | Buy | $18.00 | +310.02% | Reiterates | a month ago |
Dyne Therapeutics IncDYN | 3 | Buy | $47.00 | +85.70% | Reiterates | a month ago |
Diamedica Therapeutics IncDMAC | 4 | Buy | $6.00 | +137.15% | Reiterates | a month ago |
Avadel Pharmaceuticals PLCAVDL | 7 | Buy | $29.00 | +59.69% | Maintains | 2 months ago |
Tarsus Pharmaceuticals IncTARS | 3 | Buy | $59.00 | +87.72% | Reiterates | 2 months ago |
Cybin IncCYBN | 2 | Buy | $4.00 | +1,042.86% | Reiterates | 8 months ago |
Mediwound LtdMDWD | 3 | Buy | $36.00 | +93.44% | Maintains | 8 months ago |
Simulations Plus IncSLP | 4 | Buy | $67.00 | +47.74% | Reiterates | 10 months ago |
Harmony Biosciences Holdings IncHRMY | 4 | Buy | $69.00 | +123.23% | Reiterates | a year ago |
Mind Medicine IncMNMD | 2 | Buy | $22.00 | N/A | Reiterates | a year ago |
Icad IncICAD | 3 | Buy | $4.00 | N/A | Maintains | a year ago |
Processa Pharmaceuticals IncPCSA | 3 | Buy | $60.00 | N/A | Maintains | a year ago |
Bionano Genomics IncBNGO | 2 | Buy | $90.00 | N/A | Maintains | a year ago |
Sensei Biotherapeutics IncSNSE | 1 | Buy | $5.00 | N/A | Upgrades | 2 years ago |
9 Meters Biopharma IncNMTRQ | 1 | Buy | $100.00 | N/A | Maintains | 2 years ago |
Aquestive Therapeutics IncAQST | 1 | Buy | $8.50 | N/A | Initiates Coverage On | 2 years ago |
Sera Prognostics IncSERA | 2 | Buy | $11.00 | N/A | Maintains | 2 years ago |
Dermtech IncDMTK | 2 | Buy | $23.00 | N/A | Maintains | 2 years ago |
Mdxhealth SaMDXH | 1 | Buy | $18.00 | N/A | Assumes | 2 years ago |
Otonomy IncOTIC | 1 | Buy | $6.00 | N/A | Maintains | 2 years ago |
Compass Pathways PLCCMPS | 1 | Buy | $50.00 | N/A | Initiates Coverage On | 3 years ago |
Strongbridge Biopharma PLCSBBP | 2 | Hold | $3.25 | N/A | Downgrades | 3 years ago |
Savara IncSVRA | 1 | Buy | $4.00 | N/A | Initiates Coverage On | 3 years ago |
Flexion Therapeutics IncFLXN | 1 | Buy | $19.00 | N/A | Initiates Coverage On | 4 years ago |
Galmed Pharmaceuticals LtdGLMD | 1 | Buy | $270.00 | N/A | Initiates Coverage On | 4 years ago |
Intercept Pharmaceuticals IncICPT | 3 | Strong Buy | $130.00 | N/A | Upgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.